Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.19 -0.05 (-0.21%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up
The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine. 
Via Benzinga
3 Healthcare Stocks with Questionable Fundamentals
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session.
Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity. 
Via Chartmill
BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatment
Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares. 
Via Stocktwits
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
Via The Motley Fool
RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report
Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices. 
Via Benzinga
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Steady growth and dividend increases over decades can make investors remarkably wealthy. 
Via The Motley Fool
Topics Economy
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment. 
Via Investor's Business Daily
2 Weight Loss Drug Stocks That Are Screaming Buys in June
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings. 
Via The Motley Fool
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks. 
Via Benzinga
Vaccine Stocks Alert: Has RFK Jr.'s CDC Panel Shakeup Sent Retail Traders To The Sidelines?
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust." 
Via Stocktwits
Topics Government
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition. 
Via Investor's Business Daily
Topics Government
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36. 
Via Stocktwits
Topics Government
These S&P500 stocks are the most active in today's session
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest. 
Via Chartmill
Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves
The meeting follows an executive order from President Trump last month, which directed drugmakers to lower medicine prices to the levels paid by other high-income countries. 
Via Stocktwits
Topics Artificial Intelligence Government
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Should You Buy Pfizer Stock Right Now?
Via The Motley Fool
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients 
Via Benzinga
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts
U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health... 
Via Benzinga
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Via The Motley Fool
Topics Intellectual Property Retirement
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
A volatile stock market represents an ideal opportunity for long-term investors to pounce. 
Via The Motley Fool
Topics Stocks
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
Via Investor Brand Network
Topics Lawsuit
S&P 500 Earnings Stun The Street In Q1 With Broad-Based Beats, Double-Digit Growth
Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet. 
Via Benzinga
Topics Stocks
These 2 Dow Stocks Are Set to Soar in 2025 and Beyond
Apple and Cisco could generate surprising gains over the next few years. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in June
Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.